Functioning Disturbance in Chronic Back Pain: Altered Muscle Metabolism

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by Oslo University Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
The Research Council of Norway
Information provided by (Responsible Party):
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT01593839
First received: May 4, 2012
Last updated: May 7, 2012
Last verified: May 2012
  Purpose

The main objective of this study is to investigate the muscle metabolism in individuals with chronic non-specific low back pain (CNSLBP) to enhance our understanding of chronic back pain.


Condition
Chronic Non-specific Low Back Pian

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Functioning Disturbance in Chronic Back Pain: Altered Muscle Metabolism

Resource links provided by NLM:


Further study details as provided by Oslo University Hospital:

Biospecimen Retention:   Samples Without DNA

Interstitial


Estimated Enrollment: 6
Study Start Date: May 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   30 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Persons referred to Hospital of rehabilitation due to chronic non-specific low back pain

Criteria

The NSCBP group:

  • At least 6 patients will be included in this study.
  • All patients referred to Vestfold Hospital Trust, Kysthospitalet, diagnosed with chronic NSCBP >3 months duration will be invited to participate in the study. The invitation will be in a written form.

Exclusion Criteria:

  • anamnesis of medical or drug abuse,
  • surgery on the musculoskeletal system of the trunk,
  • known congenital malformation of the spine or scoliosis,
  • body mass index > 27 kg/m2,
  • systemic-neurological-degenerative disease,
  • history of stroke,
  • psychiatric disorder,
  • pregnancy and abnormal blood pressure. The subjects will be asked not to use any medications except for paracetamol preparations one week before examination and instructed not to perform any back-straining exercise for 48 h prior to the study, except for ordinary daily working and/or leisure activities.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01593839

Contacts
Contact: Aage Indahl, PhD, MD (+47)33134045 aage.indahl@siv.no
Contact: Vegard Pihl Moen, PT, MSc (+47)33134097 vegard.pihl.moen@siv.no

Locations
Norway
Kysthospitalet, Vestfold Hospital Trust Recruiting
Stavern, Norway, 3290
Contact: Aage Indahl, MD, PhD    +4791765888    aage.indahl@siv.no   
Contact: Vegar Phil Moen, MS    +4792438242    Vegar.Phil.Moen@siv.no   
Sponsors and Collaborators
Oslo University Hospital
The Research Council of Norway
  More Information

No publications provided

Responsible Party: Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01593839     History of Changes
Other Study ID Numbers: 182006/V50, 08/5253 Personvernombudet RRHF
Study First Received: May 4, 2012
Last Updated: May 7, 2012
Health Authority: Norway:National Committee for Medical and Health Research Ethics

ClinicalTrials.gov processed this record on September 30, 2014